title: Quadruple induction immunosuppression after liver transplantation with interleukin-2 receptor antibody (BT 563) is equally effective and better tolerated than antithymocyte globulin induction therapy.
authors: Department of Surgery, UKRV, Freie Universitat Berlin, Germany.
authors: P
authors: P
authors: Neuhaus
authors: W O
authors: WO
authors: Bechstein
authors: G
authors: G
authors: Blumhardt
authors: R
authors: R
authors: Steffen
authors: H
authors: H
authors: Keck
authors: P
authors: P
authors: Lemmens
authors: J M
authors: JM
authors: Langrehr
authors: H
authors: H
authors: Schlag
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016031:Liver Transplantation / Q000276:immunology*; D011241:Prednisone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; C079843:inolimomab; D001379:Azathioprine; D011241:Prednisone